DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
|Date Filed||Document No.||Description||Snippet||Link To Document|
|2019-12-12||1||Complaint||2 of United States Patent Nos. 10,500,216 (“the ʼ216 patent” or “the patent-in-suit”), owned by Corcept… This complaint is an action for patent infringement under the patent laws of the United States, 35 U.S.C… of the ’216 patent, constitutes infringement of one or more of the claims of that patent under 35 U.…infringement of any claim of the patent-in-suit, until after the expiration of the patent-in-suit, or any later … COMPLAINT FOR PATENT v.||External link to document|
|2020-02-19||26||Joint Discovery Plan||States Patent No. 10,500,216 (“the ’216 patent”). Generally, the claims of the ’216 patent cover… Response: This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…infringement of one or more claims of the ’216 patent, and that Teva’s ANDA Products will infringe those… after FDA approval. Teva asserts that the ’216 patent is invalid and/or not infringed. 2. Have …occurred in this litigation or relating to the ’216 patent. In Civil Action No. 18-3632, Teva produced a copy||External link to document|
|>Date Filed||>Document No.||>Description||>Snippet||>Link To Document|